Simon Clawson

906 total citations · 1 hit paper
9 papers, 623 citations indexed

About

Simon Clawson is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Simon Clawson has authored 9 papers receiving a total of 623 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in Simon Clawson's work include Lymphoma Diagnosis and Treatment (5 papers), Lung Cancer Treatments and Mutations (3 papers) and Viral-associated cancers and disorders (2 papers). Simon Clawson is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Lung Cancer Treatments and Mutations (3 papers) and Viral-associated cancers and disorders (2 papers). Simon Clawson collaborates with scholars based in United Kingdom, Netherlands and Poland. Simon Clawson's co-authors include Nicola Muirhead, Beverley J. Hunt, David Isenberg, Caroline J Doré, Munther A. Khamashta, Hannah Cohen, Jan Walewski, Andrew Jack, John Radford and Sally Stenning and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Urology.

In The Last Decade

Simon Clawson

9 papers receiving 611 citations

Hit Papers

Rivaroxaban versus warfarin to treat patients with thromb... 2016 2026 2019 2022 2016 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
    2016 278 citations Hannah Cohen, Beverley J. Hunt et al. The Lancet Haematology profile →

Peers

Simon Clawson
Ben G. F. Heggelman Netherlands
Juan Herrada United States
Reyhan Diz Küçükkaya Türkiye
José Ordi-Ros Spain
M. Taraborelli Italy
Mark Nesbit United States
Irama Villar Spain
Sonja Burgstaller Austria
Meliha Nalçacı Türkiye
María Teresa Camps Spain
Ben G. F. Heggelman Netherlands
Simon Clawson
Citations per year, relative to Simon Clawson Simon Clawson (= 1×) peers Ben G. F. Heggelman

Countries citing papers authored by Simon Clawson

Since Specialization
Citations

This map shows the geographic impact of Simon Clawson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Clawson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Clawson more than expected).

Fields of papers citing papers by Simon Clawson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Clawson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Clawson. The network helps show where Simon Clawson may publish in the future.

Co-authorship network of co-authors of Simon Clawson

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Clawson. A scholar is included among the top collaborators of Simon Clawson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Clawson. Simon Clawson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Cohen, Hannah, Beverley J. Hunt, Maria Efthymiou, et al.. (2016). Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. The Lancet Haematology. 3(9). e426–e436. 278 indexed citations breakdown →
2.
Cohen, Hannah, Benjamin Hunt, Deepa J. Arachchillage, et al.. (2015). Raps (rivaroxaban in antiphospholipid syndrome): a prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. UCL Discovery (University College London). 1 indexed citations
3.
4.
5.
Harland, S.J., Howard Kynaston, Kenneth M. Grigor, et al.. (2007). A Randomized Trial of Radical Radiotherapy for the Management of pT1G3 NXM0 Transitional Cell Carcinoma of the Bladder. The Journal of Urology. 178(3). 807–813. 46 indexed citations
6.
Friedberg, Jonathan W., Jennifer L. Kelly, Simon Clawson, et al.. (2005). Outcome of Patients > Age 40 with Burkitt Lymphoma (BL) Treated with Aggressive Chemotherapuetic Regimens: Results from the International Burkitt Lymphoma Collaborative Group.. Blood. 106(11). 928–928. 3 indexed citations
7.
Johnson, Peter, John Radford, Michael Cullen, et al.. (2005). Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Journal of Clinical Oncology. 23(36). 9208–9218. 95 indexed citations
8.
Hancock, Bruno C., John Radford, M.H. Cullen, et al.. (2004). Randomised controlled trial of ABVD vs. two multi-drug regimens (MDRs) for advanced Hodgkin's lymphoma (HL): Initial results of UKLG LY09 (ISRCTN97144519).. British Journal of Cancer. 91. 1 indexed citations
9.
Radford, John, M.H. Cullen, Matthew R. Sydes, et al.. (2003). Randomised comparison of ABVD with two multi-drug regimens (MDRs) in the treatment of advanced Hodgkin lymphoma (HL): Initial results of the UKLG LY09 study (ISRCTN 97144519).. Blood. 102(11). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ben G. F. Heggelman Breakdown of academic impact, for papers by Juan Herrada Breakdown of academic impact, for papers by Reyhan Diz Küçükkaya Breakdown of academic impact, for papers by José Ordi-Ros Breakdown of academic impact, for papers by M. Taraborelli Breakdown of academic impact, for papers by Mark Nesbit Breakdown of academic impact, for papers by Irama Villar Breakdown of academic impact, for papers by Sonja Burgstaller Breakdown of academic impact, for papers by Meliha Nalçacı Breakdown of academic impact, for papers by María Teresa Camps
Rankless by CCL
2026